<DOC>
	<DOCNO>NCT00003698</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness combretastatin A4 phosphate treat patient advanced malignant solid tumor .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity profile , include dose limiting toxicity , maximum tolerate dose ( MTD ) combretastatin A4 phosphate patient advance solid malignant tumor . II . Determine pharmacokinetics combretastatin A4 phosphate . III . Assess effect combretastatin A4 phosphate tumor blood flow use PET MRI scan technique , establish dose effect occur . IV . Recommend dose combretastatin A4 phosphate phase II evaluation base tumor blood flow effect MTD . V. Evaluate possible antitumor effect regimen patient . OUTLINE : This open label , dose escalation , multicenter study . Patients receive IV combretastatin A4 phosphate 10 minute week 3 week . Patients experience unacceptable toxic effect begin individual dose escalation , receive maximum 3 dose level 2 week rest dose level . Dose escalation stop 2 patient experience dose limiting toxicity ( DLT ) particular dose level . Once DLT establish , least 6 patient treat low dose determine maximum tolerate dose . Patients may receive 6 course 3 infusion . Patients follow 4 week . PROJECTED ACCRUAL : Approximately 30-35 patient accrue study .</detailed_description>
	<mesh_term>Fosbretabulin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor amenable standard curative therapy refractory conventional therapy Tumor suitable MRI PET image No active brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : At least 4 month Hematopoietic : WBC least 4,000/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 1.17 mg/dL ALT AST less 2 time upper limit normal ( ULN ) Alkaline phosphatase less 2 time ULN ( unless due liver bone metastasis ) Renal : Creatinine le 1.5 mg/dL Cardiovascular : No ischemic heart disease Other : Not pregnant nursing Fertile patient must use effective contraception least 4 week , , 4 week study No serious medical condition serious infection within past 28 day No active concurrent malignancy , except : Carcinoma situ cervix Adequately treat basal squamous cell carcinoma skin No autoimmune disorder No inflammatory bowel disease No diabetes PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 6 week since prior nitrosoureas mitomycin recover Endocrine therapy : Concurrent steroid use allow Radiotherapy : At least 6 week since prior radiotherapy ( except radiotherapy small isolated field include significant area bone marrow ) recover No prior radiotherapy tumor site ( ) image MRI/PET scan use assess tumor response Surgery : No concurrent open surgery Other : At least 4 week since prior anticancer therapy recover No concurrent heparin warfarin Concurrent NSAIDs allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>